Working… Menu

LungPoint ATV for Biopsy in Patients Undergoing Lobectomy (LABEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02130115
Recruitment Status : Completed
First Posted : May 5, 2014
Last Update Posted : May 5, 2014
Information provided by (Responsible Party):
Broncus Medical Inc

Brief Summary:
The purpose of this study is to evaluate the safety and performance of the LungPoint ATV System.

Condition or disease Intervention/treatment Phase
Lung Cancer Device: LungPoint ATV System Not Applicable

Detailed Description:

The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs. This feasibility study is being conducted to assess the ability of the investigator to access and sample tissue using this system in patients undergoing lobectomy or pneumonectomy. Navigation to and sampling of the patient's lung cancer tumor is conducted immediately prior to the scheduled lobectomy or pneumonectomy.

Note: This study was conducted as a single-center feasibility clinical trial to determine the feasibility of this device. The primary outcome measures related only to feasibility and not to health outcomes. Therefore it was not registered on prior to the start of enrollment. Subsequently, it was determined that the results were compelling and therefore it was registered to facilitate publication.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: LungPoint ATV for Biopsy in Patients Undergoing Lobectomy
Study Start Date : March 2013
Actual Primary Completion Date : September 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Intervention Details:
  • Device: LungPoint ATV System
    The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.

Primary Outcome Measures :
  1. Ability to complete procedure using system [ Time Frame: At completion of procedure ]
    The proportion of cases (attempted nodules) in which the procedure could be substantially completed by the investigator divided by the number of cases (nodules) for which at least one attempt to pass any LungPoint study device into the bronchoscope was made.

Secondary Outcome Measures :
  1. Proportion of nodules biopsied yielding tissue sufficient for diagnosis [ Time Frame: Upon asssessment of histology of tissue sample taken during procedure ]
    The number of nodules with at least one biopsy sufficient for a tissue diagnosis divided by the number of nodules sampled using the LungPoint ATV system.

  2. Number of significant adverse events [ Time Frame: Up through lobectomy of lobe at end of procedure ]
    The number of SAEs rated as probably or definitely related to the study device and/or procedure divided by the number of patients in whom an attempt at study device use was made. The adverse events specifically tracked in this study are hemoptysis and pneumothorax.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Surgical candidates age 21-75 years at screening
  2. Known or suspected lung cancer or intrapulmonary metastatic disease with SPN greater than 10 mm and less than 40mm in largest dimension
  3. No known endobronchial tumor
  4. Tumor located anywhere in parenchymal tissue >1 cm from pleura and accessible bronchoscopically through a POE.
  5. Willing to participate in all aspects of study protocol for duration of study
  6. Able to understand study requirements
  7. Signs study-related informed consent document

Exclusion Criteria:

  1. Any contraindication to bronchoscopy, for example: (a.) Untreatable life-threatening arrhythmias, (b.) Inability to adequately oxygenate the patient during the procedure, (c.) Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated), (d.) Recent myocardial infarction, (e.) Previously diagnosed high-grade tracheal obstruction, (f.) Uncorrectable coagulopathy.
  2. Known coagulopathy
  3. Platelet dysfunction or platelet count < 100 x 103 cells/mm3
  4. History of major bleeding with bronchoscopy
  5. Pulmonary hypertension with mean PAP >25 mm
  6. Moderate-to-severe pulmonary fibrosis
  7. Moderate to severe emphysema or COPD with FEV1 <60% predicted or RV >200% predicted
  8. Bullae >5 cm located in vicinity of target SPN or ATV tunnel
  9. Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example: (a.) ASA class > 3, (b.) > stage 3 heart failure, (c.) severe cachexia, (d.) severe respiratory insufficiency or hypoxia
  10. Ongoing systemic infection
  11. Contraindication to general anesthesia
  12. Chronic use of anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel)
  13. Participation in any other study in last 30 days
  14. Prior thoracic surgery on the same side of the lung as the SPN
  15. Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study.
  16. Life expectancy of less than one year.
  17. Patients with known intrapulmonary metastases of extrapulmonary cancer/tumors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02130115

Layout table for location information
Heidelberg, Germany, 69126
Sponsors and Collaborators
Broncus Medical Inc
Layout table for investigator information
Principal Investigator: Felix Herth, MD Heidelberg University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Broncus Medical Inc Identifier: NCT02130115    
Other Study ID Numbers: Protocol 40
First Posted: May 5, 2014    Key Record Dates
Last Update Posted: May 5, 2014
Last Verified: May 2014